Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model
- Supplementary File 1:
ZIP-Document (ZIP, 298 KiB)
Hazekawa, M.; Nishinakagawa, T.; Hosokawa, M.; Ishibashi, D. Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model. Pharmaceutics 2022, 14, 815. https://doi.org/10.3390/pharmaceutics14040815
Hazekawa M, Nishinakagawa T, Hosokawa M, Ishibashi D. Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model. Pharmaceutics. 2022; 14(4):815. https://doi.org/10.3390/pharmaceutics14040815
Chicago/Turabian StyleHazekawa, Mai, Takuya Nishinakagawa, Masato Hosokawa, and Daisuke Ishibashi. 2022. "Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model" Pharmaceutics 14, no. 4: 815. https://doi.org/10.3390/pharmaceutics14040815